Doctor-prescribed compounded Semaglutide lose up to 1520% of body weight with once-weekly injections, delivered to your door
To better protect this improved formulation, Johnson & Johnson submitted an international patent application PCT/US2016/059893 in November 2016 to safeguard the Daratumumab subcutaneous injection formulation
Market Segmentation Global Glucagon-Like Peptide-1 Agonists Market Size, Share & Industry Analysis, By Product Type (Short-Acting GLP-1 Agonists, Long-Acting GLP-1 Agonists), By Route of Administration (Injectable, Oral), By Application (Type 2 Diabetes, Obesity Management, Cardiovascular Disease Management), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa), Analysis and Forecast 20262035 Global Glucagon-Like Peptide-1 Agonists Market Size & Statistics The Market size of global glucagon-like peptide-1 agonists was estimated to be worth USD 46.18 Billion in 2025
NO.8 Comirnaty Company: Pfizer/BioNTech 2024 worldwide sales forecast: $10.79 billion Comirnaty is a COVID-19 mRNA vaccine co-developed by Pfizer and BioNTech
There is a strong interest in developing obesity treatments based on glucagon-like peptide-1 (GLP-1) agonists, which have proved to limit morbidity and mortality in type 2 diabetes
Contact us to learn how OZMOSIs data intelligence platform can enhance your teams strategic initiatives.
